A preliminary study shows GLP-1 drugs like Ozempic may slow alcohol absorption and reduce feelings of intoxication.
Hims & Hers' Dr. Craig Primack explains why personalized care, not just GLP-1s, is the key to lasting weight loss success.
Novo Nordisk ends its Wegovy deal with Hims & Hers, citing safety concerns as the telehealth firm pushes back.
Found is now offering Wegovy and Zepbound through direct-to-consumer pharmacy programs, expanding access to GLP-1 medications.
WeightWatchers has filed for Chapter 11 bankruptcy as part of a financial restructuring and a renewed focus on telehealth.
Hims & Hers and Novo Nordisk are teaming to expand affordable access to weight loss treatments, launching a bundled Wegovy offering.
Weight-reducing drugs such as Ozempic and Wegovy are changing how Americans eat, paving the way for nutrition brands to make their mark.
Luxury fitness brand Equinox is creating a program designed to help Ozempic and Wegovy users build long-term, healthy habits.
Hims' new platform will roll out just in time for New Year’s resolutions, but will lean on generic medications instead of highly popular GLP-1s.
Novo Nordisk has filed lawsuits against wellness clinics and spas for selling non-FDA-approved versions of its weight-loss drugs.
Sign Up to Our Newsletter
